Epithalon

Home › Research › Epithalon

View Epithalon in the AxYn range →

Snapshot

Chemistry and make-up

Epithalon is a very small linear tetrapeptide, Ala-Glu-Asp-Gly. It has no cysteine (no disulfide), no metal binding, and no modifications in the standard form; it is essentially a short, acidic (two carboxylic-acid side chains from Glu and Asp) water-soluble peptide. It was designed at the St Petersburg Institute of Bioregulation and Gerontology as a synthetic short-peptide analog of epithalamin, a pineal-gland extract, within Khavinson’s “peptide bioregulator” programme. Because the molecule is so short and simple, synthesis is easy and identity/QC is straightforward by MS and HPLC; the commercial risk is less about hard chemistry and more about whether a cheap, easy-to-make peptide is being sold on the back of overstated biology. Sold as free base or acetate; state the salt on the CoA. Verify formula/MW against PubChem CID 219042 (C14H22N4O9, ~390.35 g/mol), matching the brief.

What it is studied for (evidence)

• Mechanism (in-vitro telomerase, now with an independent replication [A]): the headline claim is telomerase activation. The primary source is Khavinson, Bondarev and Butyugov, who reported that Epitalon reactivated hTERT expression, restored telomerase activity and elongated telomeres in telomerase-negative human fetal fibroblasts, extending replicative capacity past the Hayflick limit (Khavinson et al., *Bull Exp Biol Med* 2003, PMID 12937682) [A]. That finding is no longer single-group: a 2025 independent, peer-reviewed in-vitro study from Brunel University London reported dose-dependent telomere lengthening via telomerase upregulation (and ALT in cancer lines, but not in normal cells) in human epithelial and fibroblast lines (Al-Dulaimi et al., *Biogerontology* 2025, PMC12411320) [A]. Note a published correction (Nov 2025) to that paper fixed several figures. A secondary claim is pineal/melatonin and circadian normalisation in ageing (overview review, PMC11943447) [A].
• Animal data: subcutaneous Epitalon reportedly increased mean lifespan (~12% in one SHR mouse study) and reduced spontaneous tumour/lymphoma incidence in rodents [A/D — Anisimov/Khavinson group, not independently replicated]. Interesting, but from the originating programme.
• The central caveat (must be stated plainly): the in-vitro telomerase story now has one recent independent replication, but the wider evidence base remains thin and heavily concentrated in the originating Russian research programme (Khavinson and collaborators), much of it older, small, and not independently replicated. Critically, there are no robust, independently replicated, controlled trials in healthy humans showing that Epithalon meaningfully lengthens telomeres or extends healthy lifespan; the human literature is small, methodologically limited, and often in Russian-language sources (RethinkPeptides / Khavinson bioregulator overview) [D]. Grade the claims accordingly: an in-vitro telomerase effect with some independent support, but human anti-ageing benefit remains unproven.
• Marketing claims vs data: vendors and anti-ageing clinics market Epithalon as a proven “telomere-lengthening”, lifespan-extending, sleep-and-longevity peptide. The data do not support that for humans. The honest position: an intriguing hypothesis (telomerase/pineal) with weak, largely unreplicated evidence, dominated by the lab that invented it.
• Human clinical status: no regulatory approval anywhere as an anti-ageing therapy; no large independent RCT.

Handling, format and stability

Supplied lyophilised for research reconstitution only (no dosing guidance here). As a small, simple, water-soluble tetrapeptide it is relatively easy to handle; store lyophilised cold and dark, and treat reconstituted solution as short-lived and cold-chain dependent. There is no special stability trap analogous to MOTS-c’s methionines; the main QC point is confirming identity and purity of a cheaply made peptide.

Regulatory and trade status

• UK/EU RUO: research use only; not an approved medicine. Anti-ageing/telomere treatment language risks “medicinal product by presentation” and should be avoided.
• US: not FDA-approved; sold as a research chemical. No recognised therapeutic use.
• Russia/CIS: the bioregulator class has a long history of use in its country of origin, but that regulatory acceptance does not transfer to UK/EU/US evidence standards and should not be cited as proof of efficacy.
• WADA (sport): not explicitly named on the 2026 Prohibited List, but as a non-approved substance (no approval by any regulatory health authority) it can be caught by the S0 catch-all, which prohibits such substances at all times. Treat sport-facing use as prohibited pending confirmation from the athlete’s anti-doping authority (WADA 2026 Prohibited List) [B].
• Customs: ordinary research-peptide profile; low individual scrutiny.

Sources

• [A] Khavinson, Bondarev, Butyugov — “Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells”, *Bull Exp Biol Med* 2003 (PMID 12937682) — https://link.springer.com/article/10.1023/A:1025493705728 *(primary source for the hTERT/telomerase claim, originating group)*
• [A] Al-Dulaimi et al. — “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity”, *Biogerontology* 2025, Brunel University London (PMC12411320; correction Nov 2025) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/ *(independent in-vitro replication)*
• [A] “Overview of Epitalon — highly bioactive pineal tetrapeptide” review (PMC11943447) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943447/
• [D] RethinkPeptides — Khavinson peptide bioregulators / Russian anti-ageing tradition — https://rethinkpeptides.com/articles/khavinson-peptide-bioregulators-the-russian-anti-aging-tradition
• [D] Peptide Protocol Wiki — Epitalon research summary — https://www.peptideprotocolwiki.com/peptides/epitalon/research
• [B] PubChem CID 219042 (Epithalon), CAS 307297-39-8
• [D] Vendor/clinic pages (revolutionhealth, metabolicjournal, peakedlabs) — commercial; publish dosing and telomere claims, which we do not use.

Plain summary

Epithalon (also spelled Epitalon) is a tiny four-amino-acid peptide, Ala-Glu-Asp-Gly, promoted for anti-ageing on the idea that it switches telomerase back on and normalises the pineal/melatonin clock. The telomerase idea rests on the originating Russian group’s 2003 fibroblast work, and it now has one independent in-vitro replication (Brunel University London, 2025), so the cell-level effect is better supported than it used to be. What is still missing is the part that matters for buyers: the animal and human evidence remains thin, old and mostly single-group, and there are no robust independent human trials showing telomere lengthening or longer healthy life. Sell it honestly as a research peptide with an interesting, partly-replicated cell mechanism but unproven human benefit, and do not repeat vendor claims that it is a proven telomere or longevity treatment.

For laboratory and research use only (RUO). Not for human or veterinary use, not for consumption, and not a medicine. Information is a research summary, not medical advice, and contains no dosing guidance.

For laboratory research use only. Not for human or veterinary use, not for consumption, and not a medicine. This is a research summary, not medical advice, and contains no dosing guidance.